“I need to get you to hit the market”…two different contrasts in blockbuster-level pharmaceutical products last year

Last year, blockbuster-level pharmaceutical products had different score sheets in the outpatient market.

The recent data of outpatient prescription expenses by UBIST analyzed multinational pharmaceutical companies’ products decreased more than KRW 5 billion.

First of all, the Gilead’s chronic hepatitis type B treatment ‘Viread (generic name: tenofovir)’ recorded KRW 74.296 billion in 2014com...